Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 4/20 | 0.77 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.67 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.65 |
| ▸ | CTSL | P07711 | 3/20 | 0.65 |
| ▸ | CTSB | P07858 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357636 | 1.00 | ALOX5 (0.78) | ALOX5MAOBABCG2NFE2L2CAPN1 | |
| SCHEMBL31676388 | 0.89 | ALOX5 (0.78) | ALOX5MAOBABCG2NFE2L2NPC1 | |
| SCHEMBL4026900 | 0.89 | LMNA (0.78) | ALOX5MAOBABCG2NFE2L2NPC1 | |
| SCHEMBL7102141 | 0.88 | ALOX5 (0.76) | ALOX5MAOBABCG2NFE2L2CTSL | |
| SCHEMBL27726386 | 0.87 | ABCG2 (0.89) | ALOX5MAOBABCG2CAPN1CTSL | |
| SCHEMBL19870465 | 0.87 | MAOB (0.79) | ALOX5MAOBABCG2CAPN1CTSL | |
| SCHEMBL8964952 | 0.87 | MAOB (1.00) | MAOBNFE2L2CAPN1CTSLCTSB | |
| SCHEMBL8964956 | 0.87 | MAOB (1.00) | MAOBNFE2L2CAPN1CTSLCTSB | |
| SCHEMBL29403206 | 0.87 | MAOB (1.00) | MAOBNFE2L2CAPN1CTSLCTSB | |
| SCHEMBL11296305 | 0.85 | ALOX5 (0.73) | ALOX5MAOBABCG2NFE2L2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2005-09-15 | — | — | US | disclosed |
| CN-1612856-A | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2005-05-04 | — | — | CN | disclosed |
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | disclosed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | disclosed |
| EP-0634927-B1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | LICA PHARMACEUTICALS AS (DK) | 2001-07-04 | — | — | EP | disclosed |
| EP-0996432-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUMINSTITUT (DK) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999000114-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUM INSTITUT (DK) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | MCL1, ENPP1, MYC | ALOX5 539/4885MAOB 1859/4885ABCG2 3826/4885 |
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | ALOX5 1298/4885MAOB 943/4885ABCG2 1177/4885 |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | ALOX5 539/4885MAOB 1859/4885ABCG2 3826/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | ALOX5 539/4885MAOB 1859/4885ABCG2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.